BACKGROUND: Epigenetic dysregulation is a hallmark of cancer, including multiple myeloma. Inhibitors of histone deacetylases (HDACs) induce DNA hyperacetylation by inhibiting removal of acetyl groups from amino tails on histone proteins, thereby uncoiling condensed chromatin favoring transcription of silenced genes, including tumor suppressor genes. Romidepsin is an HDAC inhibitor that exhibits antiproliferative and apoptotic effects against multiple myeloma cell lines. METHODS: A phase 2 trial was performed of romidepsin in patients with multiple myeloma who were refractory to standard therapy. Treatment was comprised of romidepsin (13 mg/m²) given as a 4-hour intravenous infusion on Days 1, 8, and 15 every 28 days). Thirteen patients received a median of 2 cycles of therapy (range, 1-7 cycles). RESULTS: Although no patients had an objective response, 4 of 12 patients with secretory myeloma exhibited evidence of M-protein stabilization, and several other patients experienced improvement in bone pain and resolution of hypercalcemia. CONCLUSIONS: The results of the current study demonstrate that romidepsin, as a single agent, is unlikely to be associated with a response rate of ≥30% in patients with refractory myeloma, although there was some clinical evidence suggesting a biological effect associated with therapy.
BACKGROUND: Epigenetic dysregulation is a hallmark of cancer, including multiple myeloma. Inhibitors of histone deacetylases (HDACs) induce DNA hyperacetylation by inhibiting removal of acetyl groups from amino tails on histone proteins, thereby uncoiling condensed chromatin favoring transcription of silenced genes, including tumor suppressor genes. Romidepsin is an HDAC inhibitor that exhibits antiproliferative and apoptotic effects against multiple myeloma cell lines. METHODS: A phase 2 trial was performed of romidepsin in patients with multiple myeloma who were refractory to standard therapy. Treatment was comprised of romidepsin (13 mg/m²) given as a 4-hour intravenous infusion on Days 1, 8, and 15 every 28 days). Thirteen patients received a median of 2 cycles of therapy (range, 1-7 cycles). RESULTS: Although no patients had an objective response, 4 of 12 patients with secretory myeloma exhibited evidence of M-protein stabilization, and several other patients experienced improvement in bone pain and resolution of hypercalcemia. CONCLUSIONS: The results of the current study demonstrate that romidepsin, as a single agent, is unlikely to be associated with a response rate of ≥30% in patients with refractory myeloma, although there was some clinical evidence suggesting a biological effect associated with therapy.
Authors: Madeleine Duvic; Rakshandra Talpur; Xiao Ni; Chunlei Zhang; Parul Hazarika; Cecilia Kelly; Judy H Chiao; John F Reilly; Justin L Ricker; Victoria M Richon; Stanley R Frankel Journal: Blood Date: 2006-09-07 Impact factor: 22.113
Authors: B G M Durie; J-L Harousseau; J S Miguel; J Bladé; B Barlogie; K Anderson; M Gertz; M Dimopoulos; J Westin; P Sonneveld; H Ludwig; G Gahrton; M Beksac; J Crowley; A Belch; M Boccadaro; M Cavo; I Turesson; D Joshua; D Vesole; R Kyle; R Alexanian; G Tricot; M Attal; G Merlini; R Powles; P Richardson; K Shimizu; P Tosi; G Morgan; S V Rajkumar Journal: Leukemia Date: 2006-07-20 Impact factor: 11.528
Authors: Leigh Ellis; Yan Pan; Gordon K Smyth; Daniel J George; Chris McCormack; Roxanne Williams-Truax; Monica Mita; Joachim Beck; Howard Burris; Gail Ryan; Peter Atadja; Dale Butterfoss; Margaret Dugan; Kenneth Culver; Ricky W Johnstone; H Miles Prince Journal: Clin Cancer Res Date: 2008-07-15 Impact factor: 12.531
Authors: J Arts; P Angibaud; A Mariën; W Floren; B Janssens; P King; J van Dun; L Janssen; T Geerts; R W Tuman; D L Johnson; L Andries; M Jung; M Janicot; K van Emelen Journal: Br J Cancer Date: 2007-11-13 Impact factor: 7.640
Authors: Enrique M Ocio; Constantine S Mitsiades; Robert Z Orlowski; Kenneth C Anderson Journal: Expert Rev Hematol Date: 2013-12-18 Impact factor: 2.929
Authors: Anne M Noonan; Robin A Eisch; David J Liewehr; Tristan M Sissung; David J Venzon; Thomas P Flagg; Mark C Haigney; Seth M Steinberg; William D Figg; Richard L Piekarz; Susan E Bates Journal: Clin Cancer Res Date: 2013-04-15 Impact factor: 12.531